Page 24 - Morphosys This News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys this. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys This Today - Breaking & Trending Today

MorphoSys Reports Preliminary Q2 Monjuvi U.S. Sales; Updates 2022 Guidance

MARTINSRIED (dpa-AFX) - MorphoSys AG (MOR, MPSYY.PK) reported preliminary second quarter Monjuvi U.S. net product sales of $23.3 million. For the full year of 2022, the company now expects Monjuvi ....

Jean Paul Kress ,

MorphoSys AG: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022

Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million)Update of ....

United States , United Kingdom , Kaitlyn Nealy , Thomas Biegi , Julia Neugebauer , Jean Paul Kress , Myles Clouston , Xencor Inc , Drug Administration , Us Communications , Exchange Commission , Human Immunology Biosciences Inc , Human Immunology Biosciences , Product Sales , Chief Executive Officer , Gross Margin , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Morphosy Annual Report ,

MorphoSys (NASDAQ:MOR) Shares Gap Up to $4.95

MorphoSys AG (NASDAQ:MOR – Get Rating)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $4.95, but opened at $5.33. MorphoSys shares last traded at $5.33, with a volume of 700 shares traded. Several research analysts have issued reports on MOR shares. Citigroup restated a “neutral” rating […] ....

United States , Capricorn Fund Managers Ltd , Morgan Stanley , Berenberg Bank , Deutsche Bank Aktiengesellschaft , Quadrant Capital Group , Morphosys Company Profile , Marshall Wace , Get Rating , Bank Aktiengesellschaft , Capital Group , Sys Company Profile , Nasdaq Mor ,

MorphoSys (OTCMKTS:MPSYF) Trading Down 9.1%

MorphoSys AG (OTCMKTS:MPSYF – Get Rating) shares were down 9.1% during mid-day trading on Wednesday . The company traded as low as $19.17 and last traded at $19.17. Approximately 200 shares were traded during trading, a decline of 64% from the average daily volume of 558 shares. The stock had previously closed at $21.10. The […] ....

United States , Get Rating , Otcmkts Mpsyf ,

Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47

DGAP-News: MorphoSys AG

/ Key word: Agreement/Miscellaneous

Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® in Combination with TTI-622, a Fusion. | June 13, 2022 ....

New York , United States , United Kingdom , Lance Leopold , Catalina Loveman , Chris Boshoff , Christine Chiou , Jenifer Antonacci , Development Officer , Xencor Inc , American Society Of Hematology , Pfizer Inc , Public Affairs , Group Vice , Drug Administration , Pfizer Global Product Development , Exchange Commission , Morphosys Us Inc , European Medicines Agency , Clinical Development Hematology , Incyte Enter , Clinical Trial Collaboration , Fusion Protein Directed Against , Chief Development Officer , Pfizer Global Product , Malte Peters ,